A cancer vaccine developed by Moderna and Merck reduced the recurrence of melanoma.Credit: Adam Glanzman/Bloomberg/Getty A personalized mRNA vaccine for melanoma reduced the risk of the cancer returning in a phase III clinical trial, the companies behind the trial announced this week. The vaccine — which relies on the same mRNA technology used to develop
Fidji Simo, the former OpenAI executive who cofounded the biomedical startup ChronicleBio, said she believes AI can eventually cure all diseases, but smarter models alone won’t get us there. In an X post on Monday, Simo responded to Anthropic CEO Dario Amodei, who wrote over the weekend that AI companies need to deliver concrete breakthroughs
Anthropic CEO Dario Amodei says the best way to win over AI skeptics is to deliver on the hype. In a rare post on X on Saturday, Anthropic’s CEO acknowledged the public’s mistrust of AI and said the industry can only change that by delivering tangible scientific breakthroughs. “At this point, saying that AI will
Cell culture MCF7 (HTB-22), ZR-75-1 (CRL-1500), CAMA-1 (HTB-21), MDA-MB-453 (HTB-131), MDA-MB-231 (HTB-26), OVCAR-3 (HTB-161) and Kuramochi (JCRB0098) cells were obtained from the American Type Culture Collection. MCF7 ESR1Y537S cells were provided by S. Chandarlaparty35. MCF7, ZR-75-1, MDA-MB-231 and CAMA-1 cells were cultured in RPMI-1640 medium (11875-093, Gibco) supplemented with 10% fetal bovine serum (FBS; SH30054.03,
Exploratory biomarker analyses were performed in 190 patients (nivolumab, 98 out of 229 (43%); placebo, 92 out of 232 (40%)) with evaluable paired tumour samples from screening and blood samples from ≥1 time point during the study for whole-exome sequencing (WES). These individuals constituted the biomarker-evaluable population. The most common reasons for exclusion were samples
That entrepreneur is Paul Conyngham, who says he is launching Gamgee to offer “personalised mRNA cancer vaccines for dogs.” But his ambitions go well beyond dogs — and pets — with Gamgee’s website promising the company will harness AI and genetics to develop personalized treatments for a range of diseases and species, including humans. At